The Runners And Riders In Hidradenitis Suppurativa
Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.
You may also be interested in...
A catastrophic late-stage clinical failure wipes 60% off the group’s value – and boosts a rival.
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.